Liu Aihai, Lv Jieqiang, Hu Yue, Lang Junzhe, Ma Luhang, Chen Wenbing
Gynecology Department, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
J Obstet Gynaecol Res. 2014 Apr;40(4):897-906. doi: 10.1111/jog.12333.
Recent studies suggest that misoprostol may be more effective than dinoprostone in pregnant women with unfavorable cervix. The objective here is to investigate and compare the efficacy and safety of intravaginal misoprostol and intracervical dinoprostone for labor induction, including incidence of cesarean section, vaginal delivery rate within 24 h, uterine hyperstimulation, tachysystole, oxytocin augmentation, neonatal intensive care unit (NICU) admissions, and Apgar score of less than 7 at 1 and 5 min.
Databases searched were MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials, up to July 2013. Randomized controlled trials comparing intravaginal misoprostol with intracervical dinoprostone in women with singleton pregnancy, intact membranes and unfavorable cervix (Bishop's <6) were included. Pooled relative risk, mean difference and 95% confidence intervals were calculated.
The use of misoprostol was significantly effective in increasing the rate of vaginal delivery within 24 h and less oxytocin augmentation when compared with dinoprostone. However, the incidents of uterine hyperstimulation and tachysystole were significantly higher under the misoprostol protocol than dinoprostone protocol. Furthermore, we found similar efficiency in the rate of cesarean delivery, NICU admission and Apgar score at 1 and 5 min among the study groups.
Intravaginal misoprostol appears to be more efficient for labor induction than intracervical dinoprostone; however, dinoprostone has been demonstrated to be safer because of the lower incidence of uterine hyperstimulation and tachysystole. Further high-quality studies assessing the possible effectiveness of misoprostol and dinoprostone in selected groups of patients are warranted.
近期研究表明,在宫颈条件不佳的孕妇中,米索前列醇可能比地诺前列酮更有效。本研究旨在调查并比较阴道内使用米索前列醇与宫颈内使用地诺前列酮引产的有效性和安全性,包括剖宫产率、24小时内阴道分娩率、子宫过度刺激、宫缩过速、催产素增加使用情况、新生儿重症监护病房(NICU)收治率以及1分钟和5分钟时Apgar评分低于7分的情况。
检索截至2013年7月的MEDLINE、EMBASE和Cochrane对照试验中央注册库。纳入单胎妊娠、胎膜完整且宫颈条件不佳(Bishop评分<6)的妇女中,比较阴道内使用米索前列醇与宫颈内使用地诺前列酮的随机对照试验。计算合并相对风险、平均差和95%置信区间。
与地诺前列酮相比,使用米索前列醇在增加24小时内阴道分娩率和减少催产素增加使用方面显著有效。然而,米索前列醇方案下子宫过度刺激和宫缩过速的发生率明显高于地诺前列酮方案。此外,我们发现研究组之间在剖宫产率、NICU收治率以及1分钟和5分钟时的Apgar评分方面效率相似。
阴道内使用米索前列醇引产似乎比宫颈内使用地诺前列酮更有效;然而,由于子宫过度刺激和宫缩过速的发生率较低,地诺前列酮已被证明更安全。有必要进行进一步的高质量研究,评估米索前列醇和地诺前列酮在特定患者群体中的可能有效性。